Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists

NACompletedINTERVENTIONAL
Enrollment

1,210

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

August 6, 2023

Study Completion Date

February 6, 2024

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
BEHAVIORAL

Best Practice Alert

Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.

Trial Locations (1)

06510

Cardiology/Internal Medicine Outpatient Clinics of Yale New Health System, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

collaborator

Relypsa, Inc.

INDUSTRY

lead

Yale University

OTHER